PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (Q94424927)
Jump to navigation
Jump to search
No description defined
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer |
No description defined |
Statements
PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC) (English)
D. Mahalingam
M. Patel
J. Sachdev
L. Hart
N. Halama
R. Ramanathan
J. Sarantopoulos
X. Liu
S. Yazji
D. Jäger
D. Adib
R. Kerschbaumer
M. Yoon
G. Manzur
A. Starodub
K. Sivarajan
M. Wertheim
P. Thambi
M. Jones
S. Goel
J. Nemunaitis